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Abstract
Diagnosing dementia can be challenging for clinicians, given the array of factors that contribute to changes in cognitive 
function. The Addenbrooke’s Cognitive Examination III (ACE-III) is commonly used in dementia assessments, covering the 
domains of attention, memory, fluency, visuospatial and language. This study aims to (1) assess the reliability of ACE-III to 
differentiate between dementia, mild cognitive impairment (MCI) and controls and (2) establish whether the ACE-III is useful 
for diagnosing dementia subtypes. Client records from the Northern Health and Social Care Trust (NHSCT) Memory Service 
(n = 2,331, 2013–2019) were used in the analysis including people diagnosed with Alzheimer’s disease (n = 637), vascular 
dementia (n = 252), mixed dementia (n = 490), MCI (n = 920) and controls (n = 32). There were significant differences in 
total ACE-III and subdomain scores between people with dementia, MCI and controls (p < 0.05 for all), with little overlap 
between distribution of total ACE-III scores (< 39%) between groups. The distribution of total ACE-III and subdomain scores 
across all dementias were similar. There were significant differences in scores for attention, memory and fluency between 
Alzheimer’s disease and mixed dementia, and for visuospatial and language between Alzheimer’s disease–vascular dementia 
(p < 0.05 for all). However, despite the significant differences across these subdomains, there was a high degree of overlap 
between these scores (> 73%) and thus the differences are not clinically relevant. The results suggest that ACE-III is a use-
ful tool for discriminating between dementia, MCI and controls, but it is not reliable for discriminating between dementia 
subtypes. Nonetheless, the ACE-III is still a reliable tool for clinicians that can assist in making a dementia diagnosis in 
combination with other factors at assessment.
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Introduction
As people get older, they experience changes in cognitive 
function some of which are associated with normal ageing. 
One of the challenges in clinical practice is to differentiate 
between presentations that are consistent with functional 
cognitive impairment, mild cognitive impairment (MCI), a 
dementia or something else. In most cases, those with cog-
nitive impairments will be referred to specialist memory 
services. Specialist memory services offer timely differen-
tial diagnosis, which is beneficial for the person as it allows 
for better adjustment, slowing of progression and planning 
ahead, and there are also significant savings to the health 
economy (Bamford et al. 2004; Prince et al. 2011; Pratt and 
Wilkinson 2003; Banarjee and Wittenberg 2009).
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There is no single test for dementia, and diagnosis is 
made on the basis of excluding other causes for the symp-
toms and clinical impression. Dementia assessment at a 
specialist service generally involves a formal assessment 
of cognitive function, activities of daily living, social, edu-
cational and employment history and a collateral history 
from someone who knows the person well. The person may 
also be referred for brain imaging. All of this information 
is reviewed to help make a differential diagnosis. It is most 
likely that clinicians, through clinical experience, weight 
the relative contribution of each of the multiple sources of 
information to come to a decision about diagnosis; however, 
there is no agreed weighting for this information. There is 
also no agreed process across services which means that 
there is significant variability in the assessments used at dif-
ferent services. Taken together, this leaves the potential for 
diagnostic variability across services.
Cognitive profiles vary across MCI and the different types 
of dementia. Those living with MCI typically experience 
cognitive impairment between that of normal ageing and 
mild dementia (Grundman et al. 2004). Amnestic MCI typi-
cally presents with predominant impairment in memory with 
increased likelihood of progression to Alzheimer’s (Grund-
man et al. 2004) while in non-amnestic MCI memory is pre-
served but one other cognitive domain will be affected. Peo-
ple with Alzheimer’s will have impairment in memory and at 
least one other cognitive domain such as attention, language, 
visuospatial ability and fluency. Greater impairment with 
episodic memory is seen in people with Alzheimer’s com-
pared to those with vascular dementia (Graham and Hodges 
2004; Karantzoulis et al. 2011). In contrast, people with vas-
cular dementia have worsening semantic memory, attention 
and visuospatial functioning in comparison to people with 
Alzheimer’s (Graham and Hodges 2004).
Cognitive assessment is a key factor in decision mak-
ing, and part of this process involves screening. The use of 
screening tools alone will not determine the diagnosis; how-
ever, the choice of test is still important. Different screening 
tools are used across services such as the Montreal Cognitive 
Assessment (MoCA) (Nasreddine et al. 2005), Mini-Mental 
State Examination (MMSE) (Folstein et al. 1975) and the 
Addenbrooke’s Cognitive Examination III (ACE-III). The 
original ACE was developed to help detect mild dementia 
and differentiate between Alzheimer’s disease and fronto-
temporal dementia (Mathuranath et al. 2000). It was initially 
designed as an extension to the commonly used MMSE, 
with additional neuropsychological domains incorporated 
to improve screening performance (Mathuranath et al. 2000), 
and was later revised (ACE-R) with clearly defined subdo-
main scores (Hodges and Larner 2016). The ACE-III was 
subsequently created to remove elements of the MMSE and 
address weaknesses of the ACE-R (Hsieh et al. 2013). The 
ACE-III takes around half an hour to complete and is scored 
out of 100, with higher scores corresponding to better cog-
nitive function. It incorporates five subdomains: attention, 
memory, fluency, language and visuospatial. The ACE-III 
has been validated as a screening tool for cognitive deficits 
in Alzheimer’s disease and frontotemporal dementia and has 
been translated and validated in other languages including 
Chinese, Japanese and Spanish (Wang et al. 2017; Li et al. 
2019; Takenoshita et al. 2019; Matias-Guiu et al. 2015). The 
ACE-III, MoCA and MMSE have all been recommended by 
the Department of Health and the Alzheimer’s Society in 
the UK for inclusion as part of a comprehensive cognitive 
assessment in memory clinics (Ballard et al. 2015). How-
ever, the ACE-III can more accurately detect frontotemporal 
dementia, as well as the earlier stages of dementia compared 
to MMSE (Hsieh et al. 2013; Slachevsky et al. 2004). In 
addition, ACE-III is better at identifying everyday activity 
impairments in dementia when compared to MMSE and 
MoCA (Giebel and Challis 2017). Thus, the results from 
these studies would suggest that ACE-III is preferrable when 
compared to other screening tools. While the ACE-III is 
commonly used as part of a full clinical assessment, few 
studies have looked at how reliable the ACE-III is alone for 
distinguishing between dementia and MCI, and the different 
types of dementia.
The aim of this study is to assess how reliable the ACE-
III assessment is for making a differential diagnosis between 
dementia, MCI and controls. Therefore, this study seeks to 
address the following questions: can the ACE-III help to 
differentiate between dementia, MCI and older adults who 
have not reported cognitive problems? For a person with 




The Northern Health and Social Care Trust (NHSCT) in 
Northern Ireland set up a memory service in 2013 to facili-
tate timely diagnosis and enable people with dementia to 
access appropriate supports. The NHSCT Memory Service 
accepts referrals for people who present with symptoms 
of memory problems and/or behavioural change within a 
clinical picture suggestive of a dementia. Since 2013, there 
have been over 6000 referrals to the NHSCT Memory Ser-
vice, however not everyone who attends for assessment 
has dementia. Potential outcomes of assessment include 
(1) diagnosis of a specific type of dementia, (2) diagnosis 
of MCI, (3) another condition which causes changes in cog-
nitive function treatable or untreatable and (4) no evidence 
of a physical or mental health condition. The comprehensive 
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assessment process in the NHSCT Memory Services 
involves a review of the following factors:
• Background information (education level, occupational 
history, family history of dementia, establishing whether 
the person can recall their own personal history)
• Symptoms (do they have insight into their own symp-
toms, did the person self-report cognitive difficulties, did 
their carer report cognitive difficulties, onset of symp-
toms, progression of symptoms, known previous psychi-
atric history, current mental health problems/ stressors, 
sleep problems, history of self-harm/ suicidal ideation, 
hallucinations, delusions, psychosis)
• General information (impairment in activities of daily 
living, can they drive, are they financially independent 
or do they require support, living situation)
• Health information (do they require assistance with medi-
cation, any history of falls, mobility/ movement prob-
lems, difficulty hearing, problems with eyesight, if they 
smoke or drink alcohol)
• Physical health risk factors (epilepsy, head injury, heart 
disease, stroke/ cerebrovascular accident/ transient 
ischaemic attacks, high blood pressure, recurrent infec-
tions, diabetes, peptic ulcer, high cholesterol, Asthma/ 
COPD, neurological)
• Tests (ACE-III, Bristol Activities of Daily Living, Zarit 
Caregiver Burden)
 A formal diagnosis can then be made by the psychiatrist 
based on the assessment of the aforementioned factors. Psy-
chiatrists in the NHSCT Memory Service use ICD-10 cri-
teria to classify dementia type. However, the ICD-10 codes 
are not recorded in the database.
Data provenance
This study received ethical approval from the Health 
Research Authority ethics board (ref: 17/NI/0142). Data 
were obtained from the NHSCT Memory Service. Over 
3500 patient records from dementia assessments were digit-
ised from 2013 to 2019. An overview of the person’s journey 
through the service is shown in Fig. 1. Most people were 
referred to the memory service by their GP (93%), while 
others were referred by other medical professionals or men-
tal health services (7%). Once referred, people attend for a 
comprehensive dementia assessment where they may receive 
a diagnosis of dementia, mild cognitive impairment (MCI), 
other diagnosis or no diagnosis (Fig. 1).
The outcomes of memory assessment are as follows.
• No diagnosis This group received no diagnosis of demen-
tia or MCI. These individuals may have one of a range 
of presentations, for example: mental health problems, 
CVA/ brain injury, other cognitive impairment, age-
related changes in cognitive function, Parkinson’s dis-
ease, other conditions or no evidence of physical or men-
tal health difficulty.
• Those with a specific diagnosis recorded, including Alz-
heimer’s disease, vascular dementia, mixed dementia, 
Lewy body dementia, frontotemporal dementia or MCI
• Dementia unspecified These people have presentations 
consistent with dementia, but at the time of assessment 
the exact type of dementia was unclear. These people are 
typically reviewed by a clinician at a later date and given 
a diagnosis.
• Other type of dementia Those diagnosed with another 
type of dementia, not listed above. The exact type of 
dementia was not recorded at time of assessment.
• Uncertain diagnosis This group did not receive a defini-
tive diagnosis at the time of assessment. In the database, 
this was recorded as between two or more diagnoses. 
These people are typically reviewed by a clinician at a 
later date and given a diagnosis.
Participants and exclusion criteria
Data were filtered to only those that completed the ACE-III 
in full; therefore, those who partially completed (n = 214) 
or did not complete the assessment (n = 362) were excluded 
from the present study. All individuals in the ‘no diagno-
sis’ of MCI or dementia category (n = 351) were excluded 
given the range of presentations in this cohort as mentioned 
above. Those that were diagnosed with Lewy body dementia 
(n = 15) and frontotemporal dementia (n = 8) were removed 
due to small sample sizes. Those in the dementia unspeci-
fied category (n = 59), other types of dementia (n = 24) and 
those who received an uncertain diagnosis (n = 228) were 
omitted as the exact diagnosis was not recorded at the time 
of assessment.
Additionally, a group of older adults (n = 32; ≥ 65 years) 
who had not presented to the memory service and did not 
have a diagnosis of dementia were recruited via social media, 
word of mouth and posters in drop-in centres or community 
groups, to provide comparative ‘control’ data. These par-
ticipants completed the same dementia assessment, includ-
ing the ACE-III, administered by a trained memory service 
practitioner using similar protocols to those employed in the 
memory service. The intention was to recruit 100 individu-
als with no reported cognitive problems as controls for the 
study; however, this sample size was not achieved due to the 
COVID-19 pandemic.
The final study cohort included 2,331 data records on 
2,176 people. A total of 2,023 (93%) people used the service 
only once, of which 151 (6.9%) used the service twice and 2 
(0.1%) people attended three times.
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Data analysis
R programming language and RStudio (version 3.6.0) 
were used for all data analyses. Exploratory analysis was 
carried out to investigate age, sex, total ACE-III score 
and scores for the ACE-III domains (attention, memory, 
fluency, language and visuospatial). ACE-III total and 
domain scores for the diagnostic groups were visualised 
using boxplots and density plots and were assessed for 
normality using Shapiro–Wilk tests. For all features, 
p < 0.05 which suggested the data was not normally 
distributed. This was confirmed by visual inspection of 
histograms/ boxplots, indicating nonparametric testing 
should be applied. Kruskal–Wallis tests were performed 
across diagnostic groups for age, ACE-III total and 
domain scores, with p < 0.05 considered to be statisti-
cally significant. Post hoc pairwise Wilcoxon rank sum 
tests were carried out using Bonferroni correction for 
multiple testing. A Chi-squared test was used to compare 
proportions of gender across diagnostic groups. Violin 
plots were produced, which combine the boxplot and den-
sity plot to better illustrate summary statistics and distri-
bution in one plot (Hintze and Nelson 1998). Pairwise 
comparisons for total ACE-III score and ACE-III domain 
scores across diagnostic groups were visualised using 
a tile plot, with statistical significance shown for each 
comparison.
Plots showing estimated kernel densities were produced 
to compare total ACE-III score for all dementias (Alzhei-
mer’s disease, vascular dementia and mixed dementia), MCI 
and controls. Based on the results of the pairwise compari-
sons that were significant, additional density plots were pro-
duced for a subset of the ACE-III domains across dementia 
diagnoses. The overlapping coefficient, which is the over-
lapping area under two probability density functions, was 
calculated for each of these comparisons.
As the maximum score differs for each ACE-III domain, 
scores were normalised by rescaling the data points between 
0 and 100 (Eq. 1).
Eq. 1: Formula for normalisation where  xi is a data point 





max (x) −min (x)
∗ 100
Fig. 1  Overview of the person’s journey with the NHSCT Memory Service, including those who were included and excluded from the study. 
Additional path shown for control participants who were not referred to the memory service but were recruited to the study (bottom left)
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For each domain, the normalised mean scores were visu-
alised using a line plot for comparisons across diagnostic 
groups. The relative differences between mean scores across 
each of the ACE-III domains were compared for all demen-
tias, MCI and controls. Kruskal–Wallis tests were performed 
to compare ACE-III domain scores for all dementias, MCI 
and controls, with p < 0.05 considered to be statistically sig-
nificant. Post hoc pairwise Wilcoxon Rank Sum tests were 
carried out using Bonferroni correction for multiple testing.
Receiver operating characteristic (ROC) curves were plot-
ted to assess the optimal cut-off points for the detection of 
MCI and dementia from controls, and dementia from MCI. 
Maximum Youden index (Youden index = sensitivity + spec-
ificity–1) was used to determine the optimal cut-offs.
Results
Over half of people in this study were female (62%), with 
a smaller proportion of males (38%), and the average age 
was 79.6 (SD 7.5). Age was significantly different across 
diagnostic groups (p < 0.001, Table 1). Post hoc testing 
revealed that there were no significant differences in mean 
age across the dementia groups; however, people diagnosed 
with MCI were significantly younger on average compared 
to the dementia groups (p < 0.05), and the control group 
were also significantly younger on average (p < 0.05) com-
pared to the MCI and dementia groups. Across diagnoses, 
proportions of gender were significantly different (p < 0.001, 
Table 1). Over 70% of people diagnosed with Alzheimer’s 
disease were female and around 60% of people with mixed 
dementia, MCI and controls were female (Table 1). Vascular 
dementia was the only group with almost even split of male 
and female (Table 1).
Comparison of total ACE‑III and domain scores 
across diagnoses
ACE-III total and domain scores were significantly different 
across diagnoses, with higher average scores for the MCI and 
control groups compared to the dementia groups (Table 1). 
Overall, the scores for the control group were much higher 
than the MCI and dementia groups across all domains and 
total ACE-III (Fig. 2). The distribution of ACE-III total 
Table 1  Memory service client demographic information and ACE-III scores (N = 2,331)
*older adults who have not reported cognitive problems
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and domain scores was similar across all dementia groups 
(Fig. 2). People with Alzheimer’s disease displayed higher 
median scores for total ACE-III, fluency, visuospatial and 
language compared to those in the mixed and vascular 
dementia groups (Fig. 2). The MCI group attained scores 
in between those with dementia and the controls (Fig. 2). 
There was some overlap between the lowest recorded scores 
for those with MCI compared to the dementia groups; how-
ever, in general the scores were centred around the upper 
ranges of the dementia groups (Fig. 2). The distribution of 
scores for ACE-III total and memory for the controls was 
bimodal while for all other ACE-III domains the distribu-
tion was negatively skewed given most of the scores were 
high (Fig. 2).
Pairwise comparisons revealed significant differences in 
total ACE-III and domain scores between MCI and controls; 
all dementia groups and controls; MCI and all dementia 
groups; (Fig. 3, p < 0.05 for all). Significant differences in 
scores were present between mixed dementia and Alzhei-
mer’s disease for attention, memory and fluency (Fig. 3). 
Scores for visuospatial and language were significantly dif-
ferent between vascular dementia and Alzheimer’s disease 
groups (Fig. 3).
ACE‑III cut‑off analysis
The optimal cut-off for differentiating dementia from con-
trols based on the maximum Youden index is 71, with 
acceptable sensitivity (0.87) and high specificity (0.97) 
(Fig. 4, Table 2). When distinguishing dementia from indi-
viduals with no cognitive impairment, the recommended 
cut-off of 88 for screening purposes yielded high sensitivity 
(0.99) but very poor specificity (0.48). At the lower cut-
off of 82 recommended for research, specificity improved 
slightly (0.63) with comparable sensitivity (0.97). The opti-
mal cut-off for distinguishing MCI from controls was 84 
with high sensitivity (0.92) but low specificity (0.63) (Fig. 4, 
Table 2). A cut-off of 61 was identified as optimal for differ-
entiating dementia from MCI; however, the sensitivity and 
specificity were poor at 0.66 and 0.79, respectively (Fig. 4, 
Table 2).
Overlap in ACE‑III scores across diagnoses
The overlap in scores was very small (15%) when comparing 
total ACE-III between all dementias and the control group 
(Fig. 5). Roughly a third of total ACE-III scores overlapped 
between dementia–MCI (39%) and MCI–controls (35%) 
(Fig.  5). In contrast, the estimated overlap of densities 
Fig. 2  ACE-III total and domain scores across diagnoses presented as violin plots. Centre boxplots indicate median, quartiles, whiskers and out-
liers
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between the dementia subtypes showed a high proportion of 
similarity (Fig. 6). Comparing densities for visuospatial and 
language, scores overlapped by 73% and 78%, respectively, 
for Alzheimer’s and Vascular dementia (Fig. 6). Similarly, 
the density plots for attention, memory and fluency between 
Fig. 3  Pairwise comparisons for ACE-III total and domain scores across diagnoses. Significance codes; ns: p > 0.05, *: p <  = 0.05, **: 
p <  = 0.01, ***: p <  = 0.001, ****: p <  = 0.0001. All results adjusted for multiple testing using Bonferroni correction
Fig. 4  ROC curve of ACE-III for detecting dementia, MCI and con-
trols
Fig. 5  Kernel density estimations for ACE-III total between all 
dementias, MCI and controls. The overlap (%) represented by the 
shaded area is detailed above theplot
 European Journal of Ageing
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Fig. 6  Kernel density estimations for ACE-III domains between dementia groups. The overlap (%) represented by the shaded area is detailed 
above each plot
Fig. 7  Normalised mean scores for each ACE-III domain across diagnostic groups, ordered from highest to lowest for the control group. Rank 
order from highest to lowest mean score shown for all dementias, MCI and controls (bottom left)
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Alzheimer’s and mixed dementia overlapped to an even 
higher degree at 83%, 89% and 86%, respectively (Fig. 6).
Pattern across ACE‑III domain scores
Across all dementias, MCI and controls, the pattern in 
normalised mean ACE scores is fairly consistent, with all 
groups scoring lowest in fluency and highest in language 
(Fig. 7). Mean scores were highest for controls, followed by 
MCI and the three dementia groups (Fig. 7). For the con-
trol group, the highest average score across domains was 
language, followed by attention, visuospatial, memory and 
fluency (Fig. 6). In contrast, the order was slightly differ-
ent for all dementias and MCI in that the highest average 
score was language, followed by visuospatial, then atten-
tion memory and fluency (Fig. 6). On average, people with 
Alzheimer’s disease scored higher on attention, memory and 
fluency compared to those with mixed dementia (Fig. 7). 
The Alzheimer’s disease cohort scored better on average 
across visuospatial and language compared to the vascular 
dementia group (Fig. 7), and these differences in scores were 
statistically significant (p < 0.001 visuospatial, p < 0.05 lan-
guage, Fig. 3) (Table 1). 
Comparing all dementias and the control group, the 
largest difference in average score was seen in the memory 
domain (> 40%) while the smallest difference was in visu-
ospatial (~ 20%) (Fig. 8). The same order was evident when 
comparing MCI to the control group (Fig. 8) although the 
percentage differences were much smaller (~ 10–25%). In 
contrast, when comparing all dementias to MCI the larg-
est difference in average score was in the attention domain 
and the smallest difference was in language; however, the 
percentage difference in average score was small, ranging 
from ~ 10 to 20% (Fig. 8).
Discussion
This study utilised data from the NHSCT Memory Service. 
This unique resource is the first database of its kind and size 
and the first to examine the different patterns of performance 
across the ACE-III within such a diverse range of individuals 
with a dementia or MCI diagnosis compared with a control 
group.
In the NHSCT Memory Service, 62% of referrals were 
female. This figure is similar to the reported prevalence of 
dementia given 65% of people living with dementia in the 









71 0.97 0.84 0.87 0.97
MCI–control 84 0.85 0.54 0.92 0.63
Dementia–
MCI
61 0.80 0.45 0.66 0.79
Fig. 8  Difference in normalised mean scores across ACE-III domains for all dementias, MCI and controls. Ordered from highest to lowest for 
dementia–control comparison)
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UK are female (Prince et al. 2014). The gender ratio across 
different diagnostic categories varied; however, given 70% 
of people in the NHSCT Memory Service diagnosed with 
Alzheimer’s disease were female, which is relatively more 
than the proportional referral rate. Roughly 60% of mixed 
dementia and MCI diagnoses were female which highlights 
that there was a consistent proportion of males and females 
with MCI and mixed dementia. There was an almost even 
split of males and females diagnosed with vascular demen-
tia, suggesting that males referred to the service are more 
likely to have vascular dementia than females referred to the 
service. This is consistent with the findings of the Rotter-
dam study, a large population-based study which found that 
regardless of age, vascular dementia was more prevalent in 
males compared to females (Ruitenberg et al. 2001).
The results of the present study demonstrate significant 
differences in ACE-III scores between people diagnosed 
with dementia, MCI and controls. People with dementia 
attending the NHSCT Memory Service perform significantly 
worse than the control group and people with MCI in terms 
of ACE-III total score and each of the domains. Roughly one 
third of total ACE-III scores overlapped between those with 
dementia compared to MCI and for the MCI and control 
groups. The overlap in total ACE-III scores between peo-
ple with dementia and controls was even less (15%). These 
results suggest that the ACE-III is good at discriminating 
between dementia, MCI and people with no reported cogni-
tive problems.
All three groups, including people with dementia, MCI 
and the control participants scored highest in language and 
lowest in memory and fluency on average. The pattern of 
normalised mean ACE-III domain scores highlighted an 
interesting pattern across groups. It was fairly consistent 
with the exception of attention which seemed to be dispro-
portionately lower in both the dementia and MCI groups 
compared to controls. This suggests that relative impairment 
in attention is greater when there is a decline in cognition 
and this relative decline is greater in dementia than in MCI. 
This finding has the potential to be clinically helpful and 
needs further exploration.
Overall, intra-domain analysis revealed that within each 
of the groups of dementia, MCI and controls, there are simi-
lar abilities in the language and visuospatial domains, given 
there were no significant differences in scores between these 
domains. All groups also performed significantly lower on 
fluency than on language and visuospatial domains. Further 
analysis which looked at the intra-domain pairwise com-
parisons revealed some distinct patterns across these three 
groups. People with MCI and controls also have similar abil-
ity in the domain of attention in addition to language and 
visuospatial processing whereas, for people with dementia, 
ability in attention is significantly different from ability in 
the domains of language and visuospatial. This finding also 
has the potential to be clinically helpful and needs further 
exploration.
These results indicate different profiles of cognition, 
revealing distinct areas of cognitive decline progressing 
from a group reporting no cognitive problems (controls), 
through to those with MCI and people with dementia.
People with Alzheimer’s disease, vascular dementia and 
mixed dementia had similar distributions on ACE-III total 
and domain scores. There were statistically significant differ-
ences between those with Alzheimer’s and mixed dementia 
(attention, memory and fluency) and between individuals 
with Alzheimer’s and vascular dementia (visuospatial and 
language). While these differences were statistically sig-
nificant, these results are not clinically significant or rel-
evant, given that there was a high degree of overlap (> 73%) 
between these domain scores. Elamin and colleagues 
reported similar findings in their study, noting that between 
dementia subgroups there were few significant differences 
in ACE-III scores (Elamin et al. 2016).
The recommended total ACE-III cut-offs for differentiat-
ing early-onset dementia patients from healthy controls are 
82 and 88 for research and screening, respectively (Hsieh 
et al. 2013). A recent review explored the diagnostic test 
accuracy of the ACE-III for dementia and found that the 
lower threshold of 82 provided better specificity with accept-
able sensitivity (Beishon et al. 2019). However, the authors 
noted that the optimal cut-offs required future work and 
should be determined across a variety of settings such as 
secondary care services which would include the NHSCT 
Memory Service. Jubb and colleagues suggested a lower cut-
off of 81 for better sensitivity and specificity in their sample 
of patients above 75 years of age presenting to a Memory 
Clinic in England (Jubb and Evans 2015). The authors also 
recommended taking other factors into consideration such 
as years of education when using ACE-III to aid diagnosis 
of dementia (Jubb and Evans 2015). In the present study, 
we identified a lower optimal cut-off of 71 for differenti-
ating people with dementia from those with no cognitive 
impairment with acceptable sensitivity and high specificity. 
In practice, this means using a cut-off of 71 is highly likely 
to correctly predict that an individual doesn’t have dementia 
if dementia is not present. We also calculated an optimal 
cut-off score of 84 for distinguishing individuals with MCI 
from the control group with high sensitivity (0.92) but poor 
specificity (0.63). Given the control participants recruited 
for this study were individuals with no cognitive problems 
and otherwise would not normally be attending the NHSCT 
Memory Service, the cut-offs identified are more applicable 
for research purposes rather than screening.
As the ACE-III is not good at discriminating between dif-
ferent types of dementia, these results highlight the impor-
tance of the range of other factors that are taken into consid-
eration when making a differential diagnosis of dementia. 
European Journal of Ageing 
1 3
Other variables that have been shown to influence ACE-III 
scores include age and education level (Bruno and Vig-
naga 2019). Previous work has found that age significantly 
contributes to overall ACE-III score as those in older age 
groups perform worse across all domains of the ACE-III 
(Matias-Guiu et al. 2015; Cheung et al. 2015). Addition-
ally, individuals with higher levels of education (> 11 years) 
perform better on the ACE-III compared to those with low 
levels of education (Matias-Guiu et al. 2015; Jubb and Evans 
2015). Years of education are positively correlated with a 
person’s cognitive function as they age (Opdebeeck et al. 
2016) and predict lower risk of dementia late in life (Lövdén 
et al. 2020). Some believe that increasing years of education 
builds cognitive reserve, which is a concept that the brain 
develops resilience that acts as a protective factor against 
loss through ageing and disease. Studies have linked this 
to better cognitive performance in people with dementia 
(Stern 2012), but also in other neurological diseases includ-
ing Parkinson’s (Hindle et al. 2014) and multiple sclerosis 
(Santangelo et al. 2019).
The data confirm that the ACE-III total score alone can-
not be used to diagnose dementia or distinguish between the 
different types of dementia. In addition, while there are some 
different patterns of performance across the domains of the 
ACE-III in the different types of dementia, it is not clear that 
a consistent pattern emerges to be helpful in making a deci-
sion about the specific diagnosis. This study was important 
because it confirms what clinicians already believed, that 
the ACE-III is an important tool to highlight that the person 
may have dementia or MCI but is not comprehensive enough 
to differentiate between the subtype of dementia. This is not 
surprising given that the ACE-III was not designed to dif-
ferentiate between the range of dementias explored in this 
paper and instead to help differentiate between Alzheimer’s 
disease and frontotemporal dementia (Hsieh et al. 2013).
Limitations
The ACE-III scores obtained on the test during the diagnos-
tic process are the scores that were compared in the study to 
assess the reliability of ACE-III, and the test is only admin-
istered once. However, diagnosis is made on the basis of a 
comprehensive assessment as outlined in the Methods. This 
includes assessment based on clinical presentation, in com-
bination with a medical report which usually comes from 
the GP that referred the patient to the service. The GP may 
have administered another cognitive screening tool such as 
MMSE, but this is not recorded in the NHSCT Memory 
Service database. Together, all of these factors are used by 
the psychiatrists to make a formal diagnosis. The analysis 
carried out did not control for age or education level, both of 
which have been shown to influence ACE-III scores, which 
is a significant limitation. The large sample sizes meant 
that some of the ACE-III domain scores across diagnostic 
groups were statistically significant; however, these results 
were not clinically significant. The sample size of the con-
trol group (n = 32) was considerably smaller than planned 
due to the coronavirus pandemic. Additionally, the control 
group were individuals recruited for the study with no cogni-
tive impairment and normally would not be referred to the 
NHSCT Memory Service and thus may not be representa-
tive of people without dementia/ MCI referred to a memory 
service. Another limitation is the exclusion of data from 
certain groups. This study only looked at those who fully 
completed all sections of the ACE-III. There were many 
reasons people were unable to complete the ACE-III in full, 
such as tiredness, anxiety, distress, severity of cognitive dif-
ficulties, poor hearing or eyesight. A number of other groups 
were excluded including those with Lewy body dementia; 
frontotemporal dementia; unspecified diagnosis of demen-
tia; other types of dementia and those with an uncertain 
diagnosis. These groups were taken out as the group sizes 
were not large enough for analyses or the exact diagnosis 
was not known at the time of assessment. Individuals who 
received no diagnosis of MCI or dementia were excluded as 
the majority of these people had other co-morbidities affect-
ing cognitive function, and thus, they could not be included 
in the ‘control’ category. This study obtained data from the 
NHSCT Memory Service database in Northern Ireland; 
however, it is still only representative of data from a single 
location.
Conclusion
This study analysed data from the NHSCT Memory Service 
database, a unique and comprehensive data repository detail-
ing the outcome of dementia assessments. The aim of the 
study was to explore the reliability of the ACE-III in differ-
entiating between dementia, MCI and controls, and whether 
the ACE-III is useful for making a differential diagnosis on 
the type of dementia. The results of this study suggest that 
the ACE-III is good for differentiating between dementia 
and MCI; however, the test is not reliable for discriminating 
between Alzheimer’s disease, vascular dementia and mixed 
dementia. Nonetheless, the ACE-III is a useful tool for cli-
nicians that can help to make a dementia diagnosis in com-
bination with other factors at assessment. Future work will 
involve utilising the NHSCT Memory Service database to 
analyse ACE-III scores for those groups that were excluded 
from the present study and determining the impact of fac-
tors that have been shown to influence ACE-III such as age, 
gender and years in education.
Acknowledgements The authors acknowledge the Atlantic Philanthro-
pies, Department of Health and The Executive Office, Northern Ireland, 
 European Journal of Ageing
1 3
for funding as part of the Dementia Analytics and Research User Group 
project (Reference Number 17-F-1801). The authors are grateful to 
the staff from the NHSCT Memory Service in Northern Ireland and 
control participants for their time, effort and support in participating 
in this research.
Open Access This article is licensed under a Creative Commons Attri-
bution 4.0 International License, which permits use, sharing, adapta-
tion, distribution and reproduction in any medium or format, as long 
as you give appropriate credit to the original author(s) and the source, 
provide a link to the Creative Commons licence, and indicate if changes 
were made. The images or other third party material in this article are 
included in the article's Creative Commons licence, unless indicated 
otherwise in a credit line to the material. If material is not included in 
the article's Creative Commons licence and your intended use is not 
permitted by statutory regulation or exceeds the permitted use, you will 
need to obtain permission directly from the copyright holder. To view a 
copy of this licence, visit http:// creat iveco mmons. org/ licen ses/ by/4. 0/.
References
Ballard C, Alistar B, Corbett A, et al (2015) Helping you to assess cog-
nition: a practical toolkit for clinicians. https://www.wamhinpc.
org.uk/sites/default/files/dementia-practical-toolkit-for-clinicians.
pdf. Accessed 9 June 2021
Bamford C, Lamont S, Eccles M et al (2004) Disclosing a diagno-
sis of dementia: a systematic review. Int J Geriatr Psychiatry 
19:151–169
Banarjee S, Wittenberg R (2009) Clinical and cost effectiveness of 
services for early diagnosis and intervention in dementia. Int J 
Geriatr Psychiatry 24:748–754. https:// doi. org/ 10. 1002/ gps. 2191
Beishon LC, Batterham AP, Quinn TJ et al (2019) Addenbrooke’s cog-
nitive examination III (ACE-III) and mini-ACE for the detection 
of dementia and mild cognitive impairment. Cochrane Database 
Syst Rev. https:// doi. org/ 10. 1002/ 14651 858. CD013 282. pub2
Bruno D, Vignaga SS (2019) Addenbrooke’s cognitive examination III 
in the diagnosis of dementia: a critical review. Neuropsychiatr Dis 
Treat 15:441–447. https:// doi. org/ 10. 2147/ NDT. S1512 53
Cheung G, Clugston A, Croucher M et al (2015) Performance of three 
cognitive screening tools in a sample of older New Zealanders. 
Int Psychogeriatrics 27:981–989. https:// doi. org/ 10. 1017/ S1041 
61021 40028 89
Elamin M, Holloway G, Bak TH, Pal S (2016) The utility of the 
addenbrooke’s cognitive examination version three in early-onset 
dementia. Dement Geriatr Cogn Disord 41:9–15. https:// doi. org/ 
10. 1159/ 00043 9248
Folstein MF, Folstein SE, McHugh PR (1975) “Mini-mental state”. 
A practical method for grading the cognitive state of patients for 
the clinician. J Psychiatr Res 12:189–198. https:// doi. org/ 10. 1016/ 
0022- 3956(75) 90026-6
Giebel CM, Challis D (2017) Sensitivity of the mini-mental state 
examination, montreal cognitive assessment and the adden-
brooke’s cognitive examination III to everyday activity impair-
ments in dementia: an exploratory study. Int J Geriatr Psychiatry 
32:1085–1093. https:// doi. org/ 10. 1002/ gps. 4570
Graham NL, Hodges JR (2004) Distinctive cognitive profiles in Alzhei-
mer’s disease and subcortical vascular dementia. J Neurol Neuro-
surg Psychiatry 75:61–71
Grundman M, Petersen RC, Ferris SH et al (2004) Mild cognitive 
impairment can be distinguished from alzheimer disease and 
normal aging for clinical trials. Arch Neurol 61:59–66. https:// 
doi. org/ 10. 1001/ archn eur. 61.1. 59
Hindle JV, Martyr A, Clare L (2014) Cognitive reserve in Parkinson’s 
disease: a systematic review and meta-analysis. Park Relat Disord 
20:1–7
Hintze L, Nelson RD (1998) Violin plots: a box plot-density trace 
synergism. Am Stat 52:181–184
Hodges JR, Larner AJ (2016) Addenbrooke’s cognitive examinations: 
ACE, ACE-R, ACE-III, ACEapp, and M-ACE. In: Cognitive 
Screening Instruments: A Practical Approach. Springer Interna-
tional Publishing, pp 109–137
Hsieh S, Schubert S, Hoon C et al (2013) Validation of the adden-
brooke’s cognitive examination III in frontotemporal dementia and 
alzheimer’s disease. Dement Geriatr Cogn Disord 36:242–250. 
https:// doi. org/ 10. 1159/ 00035 1671
Jubb MT, Evans JJ (2015) An investigation of the utility of the adden-
brooke’s cognitive examination III in the early detection of 
dementia in memory clinic patients aged over 75 years. Dement 
Geriatr Cogn Disord 40:222–232. https:// doi. org/ 10. 1159/ 00043 
3522
Karantzoulis S, Galvin JE, Manzotti E (2011) Distinguishing Alzhei-
mer’s disease from other major forms of dementia. Expert Rev 
Neurother 11:1579–1591. https:// doi. org/ 10. 1586/ ern. 11. 155
Li X, Yang L, Yin J et al (2019) Validation study of the chinese version 
of addenbrooke’s cognitive examination iii for diagnosing mild 
cognitive impairment and mild dementia. J Clin Neurol 15:313–
320. https:// doi. org/ 10. 3988/ jcn. 2019. 15.3. 313
Lövdén M, Fratiglioni L, Glymour MM et al (2020) Education and cog-
nitive functioning across the life span. Psychol Sci Public Interes 
21:6–41. https:// doi. org/ 10. 1177/ 15291 00620 920576
Mathuranath PS, Nestor PJ, Berrios GE et al (2000) A brief cognitive 
test battery to differentiate Alzheimer’s disease and frontotempo-
ral dementia. Neurology 55:1613–1620. https:// doi. org/ 10. 1212/ 
01. wnl. 00004 34309. 85312. 19
Matias-Guiu JA, Fernández de Bobadilla R, Escudero G, et al (2015) 
Validation of the Spanish version of Addenbrooke’s Cognitive 
Examination III for diagnosing dementia. Neurol (English Ed 
30:545–551. https:// doi. org/ 10. 1016/j. nrleng. 2014. 05. 001
Nasreddine ZS, Phillips NA, Bédirian V et al (2005) The montreal 
cognitive assessment, MoCA: a brief screening tool for mild cog-
nitive impairment. J Am Geriatr Soc 53:695–699. https:// doi. org/ 
10. 1111/j. 1532- 5415. 2005. 53221.x
Opdebeeck C, Martyr A, Clare L (2016) Cognitive reserve and cog-
nitive function in healthy older people: a meta-analysis. Aging. 
Neuropsychol Cogn 23:40–60
Pratt R, Wilkinson H (2003) A psychosocial model of understanding 
the experience of receiving a diagnosis of dementia. Dementia 
2:181–199. https:// doi. org/ 10. 1177/ 14713 01203 00200 2004
Prince M, Bryce R, Ferri C (2011) World Alzheimer Report 2011: 
The benefits of early diagnosis and intervention; World Alzhei-
mer Report 2011: The benefits of early diagnosis and intervention
Prince M, Knapp M, Guerchet M, et al (2014) Dementia UK: Update 
Second Edition
Ruitenberg A, Ott A, Van Swieten JC et al (2001) Incidence of demen-
tia: does gender make a difference? Neurobiol Aging 22:575–580. 
https:// doi. org/ 10. 1016/ S0197- 4580(01) 00231-7
Santangelo G, Altieri M, Enzinger C et al (2019) Cognitive reserve and 
neuropsychological performance in multiple sclerosis: a meta-
analysis. Neuropsychology 33:379–390. https:// doi. org/ 10. 1037/ 
neu00 00520
Slachevsky A, Villalpando JM, Sarazin M et al (2004) Frontal assess-
ment battery and differential diagnosis of frontotemporal dementia 
and Alzheimer disease. Arch Neurol 61:1104–1107. https:// doi. 
org/ 10. 1001/ archn eur. 61.7. 1104
Stern Y (2012) Cognitive reserve in ageing and Alzheimer’s disease. 
Lancet Neurol 11:1006–1012
Takenoshita S, Terada S, Yoshida H et al (2019) Validation of adden-
brooke’s cognitive examination III for detecting mild cognitive 
European Journal of Ageing 
1 3
impairment and dementia in Japan. BMC Geriatr 19:123. https:// 
doi. org/ 10. 1186/ s12877- 019- 1120-4
Wang BR, Ou Z, Gu XH et al (2017) Validation of the Chinese ver-
sion of addenbrooke’s cognitive examination III for diagnosing 
dementia. Int J Geriatr Psychiatry 32:e173–e179. https:// doi. org/ 
10. 1002/ gps. 4680
Publisher's Note Springer Nature remains neutral with regard to 
jurisdictional claims in published maps and institutional affiliations.
